Sponsored by AstraZeneca, the PACIFC study was a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study of MEDI14736 (durvalumab) as Sequential Therapy in Patients with Locally advanced, unresectable non-small cell lung cancer (stage 3) who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy. The PACIFIC trial evidenced the addition of durvalumab (Imfinzi) as consolidation therapy significantly improved progression-free survival and overall survival versus placebo in patients with stage III NSCLC who did not have disease progression after 2 or more cycles of platinum-based chemoradiation. Following this study, more patients with stage III NSCLC should be eligible for immunotherapy.
The study was a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study of MEDI4736 as Sequential Therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (PACIFIC).
TrialSite News offers a link to Dr. Konstantinos Leventakos, MD, assistant professor of oncology, Mayo Clinic, on the impact of the PACIFIC trial on the stage III non-small cell lung cancer (NSCLC) treatment in Onclive to discuss the results via a video. We note that questions on this study and associated treatment remain.
MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumor’s immune-evading tactics. MEDI4736 is being developed, alongside other immunotherapies (IMTs), to empower the patient’s immune system and attack the cancer. The PACIFIC clinical trial was a global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer.
Dr. Konstantinos Leventakos, MD assistant professor of oncology, Mayo Clinic
Call to Action: Are you tracking lung cancer (NSCLC)? Dr. Leventakos is a global expert conducting clinical research out of one of the world’s top providers and investigator site Mayo Clinic.